Press Releases

New Study Shows Racial Disparities in Guideline-Concordant Care for Early-Onset Colorectal Cancer Patients
May 26, 2022
The American Cancer Society led research to be presented at the 2022 ASCO annual meeting

American Cancer Society,

 Abstract #6544

ATLANTA, May 26, 2022 — In a new large national study led by researchers at the American Cancer Society (ACS), Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their white counterparts. Differences in health insurance coverage type, a modifiable factor, according to the findings, were the largest identified contributor to the racial disparities. The study results will be presented at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7.

In the study, led by Dr. Leticia Nogueira, senior principal scientist, health services research at the American Cancer Society, more than 147,000 non-Hispanic Black and white individuals aged 20-49 years newly diagnosed with colorectal cancer during 2004-2019 were selected from the National Cancer Database. Patients who received all care recommended by the National Comprehensive Cancer Network (staging, surgery, lymph node evaluation, chemotherapy, and radiotherapy) for which they were eligible according to cancer subsite and clinical and pathological TNM stage were considered guideline-concordant. Demographic characteristics (age and sex), comorbidities, and health insurance coverage type were added sequentially to a series of multivariable models to estimate the contribution to racial disparities in receipt of guideline-concordant care. Racial disparities in time from diagnosis date (among rectal cancer patients eligible for neoadjuvant chemotherapy) and surgery date (among colon cancer patients eligible for adjuvant chemotherapy) to date of chemotherapy initiation was evaluated using restricted mean time to treatment.

Of the 84,728 colon and 62,483 rectal cancer patients included in the study, 20.8% and 14.5% were Black, respectively. Black patients were 18 and 36% less likely to receive guideline-concordant care than white patients diagnosed with colon and rectal cancer, respectively. Demographic characteristics and comorbidities combined explained less than 5% of the disparity, while health insurance coverage type explained 28.6% and 19.4% of the disparity among colon and rectal cancer patients, respectively. Restricted mean time to chemotherapy was statistically significantly longer among Black than white patients for colon (54.0 vs. 48.7 days) and rectal cancers (49.6 vs. 40.9 days), respectively.

Study authors stress improved access to care could help mitigate disparities in cancer outcomes.

# # #


About the American Cancer Society
The American Cancer Society is on a mission to free the world from cancer. We invest in lifesaving research, provide 24/7 information and support, and work to ensure that individuals in every community have access to cancer prevention, detection, and treatment. For more information, visit